DUBLIN--(BUSINESS WIRE)--The "Investigation Report on the Entecavir Market in China 2020-2024" report has been added to ResearchAndMarkets.com's offering.

According to the report, due to the lack of new antiviral drugs for Hepatitis B, the market demand is far from being satisfied. Therefore, entecavir is estimated to enjoy good market prospects and its sales volume will keep growing in the next few years. However, due to the decline in average prices, sales of entecavir in the Chinese market may continue to decline.

The number of people infected with hepatitis B virus (HBV) exceeded 100 million in China by the end of 2019, among of which 20-30 million suffering from chronic Hepatitis B. About 0.5 million Chinese is estimated to die of liver damage and liver cancer caused by chronic Hepatitis B every year, causing a loss of over CNY100 billion for society.

Entecavir, an oral deoxyguanosine drug, was developed by Bristol-Myers Squibb and was approved to enter the market by the FDA in March 2005. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd got CFDA's approval at the end of 2005 and entered the Chinese market in early 2006, followed by many generic drugs that promote market growth greatly.

According to the market research, the annual sales value of entecavir in China rose from CNY1126 million in 2013 to CNY 1996 million in 2017 and decreased to CNY1264 in 2019. Entecavir made by Sino-American Shanghai Squibb Pharmaceuticals Ltd dominates the Chinese market with a share of over 40% in 2019 by sales value.

Compared with the original nucleoside analogue, entecavir has stronger antiviral effects, faster onset, fewer side effects, and lower resistance rate, thus inhibiting HBV strongly and having a high barrier to drug resistance. Entecavir makes it possible for patients to start with monotherapy which could be successful over the long term. As is known to all, new drugs entering the anti-HBV drug market is bound to pose a threat to old ones, forming a new competitive landscape.

Key Topics Covered:

1 Related Concept of Entecavir

1.1 Indications for Entecavir

1.2 Development History of Entecavir in China

1.3 Governmental Approval for Entecavir in China

2 Survey on Sales Status of Entecavir in China, 2015-2019

2.1 Sales Value of Entecavir

2.1.1 Overall Sales Value of Entecavir in China

2.1.2 Sales Value of Entecavir by Region in China

2.2 Sales Volume of Entecavir

2.2.1 Overall Sales Volume of Entecavir in China

2.2.2 Sales Volume of Entecavir by Region in China

2.3 Sales of Entecavir by Dosage Form in China, 2015-2019

2.3.1 Sales of Entecavir Capsules in China

2.3.2 Sales of Entecavir Tablets in China

3 Major Manufacturers of Entecavir in China, 2015-2019

3.1 Market Share of Entecavir in China by Major Manufacturer

3.1.1 Market Share of Entecavir Manufacturers in China by Sales Value

3.1.2 Market Share of Entecavir Manufacturers in China by Sales Volume

3.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

3.2.1 Enterprise Profile

3.2.2 Sales of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir in China

3.3 Sino-American Shanghai Squibb Pharmaceuticals Ltd.

3.4 Jiangxi Qingfeng Pharmaceutical Co., Ltd.

3.5 Suzhou Dawnrays Pharmaceutical Co., Ltd.

3.6 Fujian Cosunter Pharmaceutical Co., Ltd.

4 Prices of Entecavir in China, 2015-2020

4.1 Average Prices of Entecavir in China

4.1.1 Average Prices of Entecavir Capsules in China 2015-2019

4.1.2 Average Prices of Entecavir Tablets in China 2015-2019

4.2 Average Prices of Sino-American Shanghai Squibb Pharmaceuticals Ltd. ' Entecavir (Baraclude)

4.3 Average Prices of Chia Tai Tianqing Pharmaceutical Group Co., Ltd.'s Entecavir (Runzhong)

4.4 Average Prices of Jiangxi Qingfeng Pharmaceutical Co., Ltd.'s Entecavir (Weiliqing)

4.5 Average Prices of Suzhou Dawnrays Pharmaceutical Co., Ltd.'s Entecavir (Leiyide)

4.6 Average Prices of Fujian Cosunter Pharmaceutical Co., Ltd.'s Entecavir (Enganding)

5 Market Outlook of Entecavir in China, 2020-2024

5.1 Forecast on Market Size

5.2 Forecast on Market Trend

Companies Mentioned

• Bristol-Myers Squibb
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Fujian Cosunter Pharmaceutical Co., Ltd.
• Jiangxi Qingfeng Pharmaceutical Co., Ltd.
• Sino-American Shanghai Squibb Pharmaceuticals Ltd.
• Suzhou Dawnrays Pharmaceutical Co., Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/sthemy

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900